Table 1.
Incidence (rate) of myocarditis after COVID-19 vaccination based on data from published large population cohort studies
| Dose | Mevorach et al. [6]a | Witberg et al. [7]b | Husby et al. [5]c | Oster et al. [9]d | Chua et al. [8]e | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Age category | 16–19 years | 20–24 years | 25–29 years | 30–39 years | All ages | 16–29 years | ≥ 30 years | All ages | 12–17 years | 12–39 years | All ages | 12–15 years | 16–17 years | 18–24 years | 25–29 years | 30–39 years | 12–17 years | All ages | |||||||||
| Vaccine type | P | P | P | P | P | P | P | P | M | P | M | P | M | P | M | P | M | P | M | P | M | P | M | P | P | P | |
| Both sexes | Both doses | NA | NA | NA | NA | NA | 5.5 (3.6–7.4) | 1.1 (0.7–1.6) | 2.13 (1.6–2.7) | NA | 1.0 (0.2–3.0) | 5.7 (3.3–9.3) | 1.6 (1.0–2.6) | 4.2 (2.6–6.4) | 1.4 (1.0–1.8) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | 18.5 (11.7–29.0) | NA |
| Male | First dose | 1.3 | 1.9 | 1.2 | 0.4 | 0.6 | 10.7 (6.9–14.5) | 2.1 (1.2–3.0) | 4.1 (3.0–5.3) | NA | NA | NA | NA | 6.3 (3.6–10.2) | 1.5 (1.0–2.2) | NA | 0.7 (0.5–1.0) | NA | 0.7 (0.5–1.2) | 1.1 (0.8–1.5) | 0.4 (0.2–0.6) | 0.5 (0.3–0.9) | 0.2 (0.1–0.4) | 0.3 (0.2–0.5) | 0.1 (0.0–0.1) | 5.6 (2.4–12.5) | NA |
| Second dose | 15.1 | 10.9 | 7.0 | 3.7 | 3.8 | NA | 7.1 (6.2–8.1) | NA | 10.6 (9.2–12.2) | 5.6 (4.7–6.7) | 5.2 (4.6–6.0) | 2.4 (1.8–3.3) | 1.7 (1.3–2.3) | 0.8 (0.6–1.1) | 0.7 (0.5–1.0) | 37.3 (27.0–51.3) | NA | ||||||||||
| Female | First dose | 0.0 | 0.0 | 0.0 | 0.0 | 0.1 | 0.3 (0.0–1.0) | 0.2 (0.0–0.5) | 0.2 (0–0.5) | NA | NA | NA | NA | 2.0 (0.7–4.8) | 1.3 (0.8–1.9) | NA | 0.0 (0.0–0.2) | NA | 0.1 (0.0–0.3) | 0.1 (0.0–0.3) | 0.0 (0.0–0.1) | 0.0 (0.0–0.3) | 0.0 (0.0–0.2) | 0.1 (0.0–0.2) | 0.1 (0.0–0.2) | 1.1 (0.2–6.6) | NA |
| Second dose | 1.0 | 2.2 | 0.0 | 0.2 | 0.5 | NA | 0.6 (0.4–1.0) | NA | 1.1 (0.7–1.7) | 0.7 (0.4–1.1) | 0.4 (0.3–0.7) | 0.8 (0.5–1.3) | 0.2 (0.1–0.5) | 0.1 (0.0–0.2) | 0.1 (0.0–0.2) | 4.8 (1.9–11.4) | NA | ||||||||||
P Pfizer-BioNTech vaccine Comirnaty, M Moderna vaccine Spikevax, NA not available
a Incidence per 100,000 vaccinated persons (95% confidence interval (CI) not available) within 21 days after first and second vaccine dose; interval between first and second dose: 21 days
b Incidence per 100,000 vaccinated persons (95% CI) within 42 days after first vaccine dose; interval between first and second dose: 21 days
c Incidence per 100,000 vaccinated persons (95% CI) within 28 days after first or second vaccine dose; median interval between first and second dose: 35 days
d Incidence per 100,000 doses administered (95% CI) within 7 days after first and second vaccine dose; interval between first and second dose: not available. Since original results were calculated per 1,000,000 doses administered, the incidence was divided by ten to calculate the incidence per 100,000 doses administered
e Incidence per 100,000 vaccinated persons (95% CI) within 14 days after first and second vaccine dose; interval between first and second dose: not available